BMO Study Says Doctors Don't Like Valeant / Allergan Merger

As behind the scenes negotiations to purchase Allergan, Inc. (NYSE:AGN) are ongoing – and ValueWalk sources who had been providing a steady stream of behind the scenes information take a more circumspect tone – comes a Bank of Montreal analysis that supports Allergan’s claims that they have won the important hearts and minds of doctors.

Valeant and Allergan fighting to win support of ophthalmologists

Doctors and more specifically ophthalmologists are a key influencer in the decision making process to purchase Allergan’s products. As reported in The Wall Street Journal, both Valeant Pharmaceuticals Intl...